Douglas Brewer, MD
Internal Medicine · Wilson, NCNPI 1437116613
Payments from drug & device makers
Across 199 payments — averaging $16.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Novo Nordisk$545
- AstraZeneca$259
- Lilly USA, LLC$242
- Corcept Therapeutics$184
- Boehringer Ingelheim$136
- plus $911 from 19 others
What the payments were for
- Food & beverage$3,33099%
- Education$251%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 79 | $1,077 |
| Novo Nordisk | 30 | $545 |
| AstraZeneca | 14 | $259 |
| Lilly USA, LLC | 15 | $242 |
| Corcept Therapeutics | 10 | $184 |
| Boehringer Ingelheim | 9 | $136 |
| Novartis | 8 | $132 |
| Bayer | 1 | $125 |
| Intercept Pharmaceuticals, Inc. | 1 | $88 |
| Johnson & Johnson(2 entities) | 5 | $83 |
| AbbVie | 5 | $75 |
| Harmony Biosciences LLC | 2 | $69 |
| Sanofi-aventis U.S. LLC | 4 | $61 |
| Pfizer | 3 | $54 |
| Ultragenyx Pharmaceutical Inc. | 2 | $45 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| Recordati_rare_diseases_inc. | 1 | $23 |
| Travere Therapeutics, Inc. | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Exact Sciences | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Cashflow Solutions, LLC | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Regeneron Healthcare Solutions, Inc. | 1 | $11 |
| Amneal Pharmaceuticals LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$125
How this compares
$3,355 in reported general payments places this provider in the 85th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 509 | $324,431 |
| JardianceEmpagliflozin | 204 | $197,113 |
| EliquisApixaban | 203 | $173,494 |
| MounjaroTirzepatide | 150 | $156,804 |
| FarxigaDapagliflozin Propanediol | 85 | $71,726 |
| TrulicityDulaglutide | 64 | $66,213 |
| OzempicSemaglutide | 60 | $64,854 |
| Praluent PenAlirocumab | 97 | $55,031 |
| KerendiaFinerenone | 56 | $47,991 |
| CreonLipase/Protease/Amylase | 15 | $32,239 |
| TradjentaLinagliptin | 28 | $27,374 |
| RybelsusSemaglutide | 25 | $22,740 |
| Repatha SyringeEvolocumab | 27 | $21,580 |
| XareltoRivaroxaban | 20 | $18,028 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $17,576 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $136 | $224,487232 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $242 | $224,396230 claims |
| PfizerEliquis | $54 | $173,494203 claims |
| Novo NordiskOzempic, Rybelsus | $545 | $87,59485 claims |
| AstraZenecaFarxiga | $259 | $71,72685 claims |
| AbbVieCreon, Linzess, Synthroid | $75 | $55,907120 claims |
| BayerKerendia | $125 | $47,99156 claims |
| Johnson & JohnsonXarelto | $83 | $18,02820 claims |
| NovartisEntresto | $132 | $9,79411 claims |
| Sanofi-aventis U.S. LLCAvapro, Lantus | $61 | $6,54632 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $11 | $3,184287 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Wilson
- Manesh PatelDurham$27.2M
- Saad UsmaniCharlotte$16.2M
- Christina KennellyCharlotte$15.4M
- John RubinoRaleigh$13M
- Adam DevoreDurham$11.8M
- Krishnakumar UdayakumarDurham$11M
- Sylvia ShoffnerCary$7.1M
- Wayne HarperRaleigh$6.7M
- Joseph MoranStatesville$6.7M
- April SalamaDurham$6.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.